

AUSTRALIAN LIFE SCIENCE

DR REUTER INVESTOR RELATIONS
SPECIALIST IN INVESTOR RELATIONS WORK ON THE
EUROPEAN CAPITAL MARKETS
DR. EVA REUTER, TEL. +49 251 7 32 862
E.REUTER@DR-REUTER.EU




EUROPE-AUSTRALIA IR
YOUR LINK TO INVESTORS IN EUROPE AND THE
AUSTRALIAN CAPITAL MARKET
TREVOR BALDOCK, TEL. +33 608 787 104
LTBALDOCK@WANADOO.FR

DR REUTER IR & EUROPE-AUSTRALIA IR



Burn Injuries and their Treatment

A minor burn is an injury almost everyone has sustained in the course of their lifetime, usually right at home, handling everyday-items such as hot coffee, a cake tin, a clothes iron. In summer, burn injuries are often caused by barbecues- in Germany alone, 3,000 people suffer burns that are treated medically every year¹. Most of the time, a burn is an injury that heals relatively quickly, maybe after causing a blister, leaving a small scar at the most. And yet 40,000 patients were hospitalized in the US 2007 with severe burns. Most had burned vital body areas such as face, hands and feet, and about one in twenty did not sur-



vive their injuries².

The causes for burns are extremely vari-

able, though most are due to thermal trauma- hot liquids, such as spilled drinks, hot solids, flames or steam. However, an electric shock caused by defibrillation or lightning may cause burns as well, as may several chemicals- mostly strong acids or bases- and radiation. The best known radiation burn is the- in summer all too common- sun burn¹.

In addition to the cause of the burn, its extent can vary. Burns are classified into degrees from 1 to 3. A sunburn is typically a first degree burn- only the most superficial layer of the skin, the epidermis, is affected and peels off after a few days when the layer beneath has healed. Second degree burns involve more of the skin, cause blistering and may sometimes leave extensive scars and even functional impairment, if they do not



¹ <http://www.webnews.de/kommentare/41593/0/Jaehrlich-3000-Unfaelle-beim-Grillen-500-erleiden-schwere-Verbrennungen.html>



² http://www.ameriburn.org/resources_factsheet.php



¹ <http://en.wikipedia.org/wiki/Burn>

This paper is a marketing communication only and does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in any of the companies listed, nor is it an inducement to make an offer or invitation with respect to any of the securities within. This information is intended solely for professional investors in the capital markets. The paper is not meant for private investors or other groups and is not to be forwarded to them. Please take note of this disclaimer.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

AUSTRALIAN LIFE SCIENCE

heal within 3 weeks. If they get infected, they have equivalent effects as third degree burns- burns that involve all layers of the skin and may even damage underlying tissue. These burns usually have to be treated surgically¹.

Treatment

Burn patients require special treatment. Of the 40,000 hospital admissions, 25,000 were to specialized burn centers². First steps that need to be taken include ending the cause for the burn as soon as possible and replacing the lost fluids, but the longer part of the treatment concentrates on managing the wounds, which are the cause for mortality and morbidity³.



Treatment options are numerous, varying according to the extent and type of burn.

Burns that are expected to heal without skin grafting are debrided, meaning that necrotic (dead) or infected tissue and other debris are removed from the wound. This creates ideal conditions for wound healing.



More serious or extensive burns need to be skin grafted: a skin transplant, which can stem from different sources, needs to be applied so as to replace the burned areas of skin. In this case, a simple debridement

is not sufficient as preparation for the following procedure, so a wound excision needs to be performed instead. This leaves an open wound prone to the loss of fluids, infection and scar contracture. To avoid these negative consequences, the wound needs to be temporarily covered until healthy skin from an unburned portion of the patients body is available for permanent skin grafting¹. One



¹American Burn Association White Paper



²http://www.ameriburn.org/resources_factsheet.php



³<http://en.wikipedia.org/wiki/Burn>



¹American Burn Association White Paper

AUSTRALIAN LIFE SCIENCE

of the following options may be used:

- ◇ **Allograft:** Most commonly, the wound is covered with a piece of skin harvested from a donor.
- ◇ **Xenograft:** skin harvested from an animal, usually a pig, can temporarily protect the wound and reduce the amount of fluids lost. In a best-case scenario, the skin autograft can be avoided, if the xenograft takes well¹.
- ◇ **Biologic dressings:** Biobrane® is a dressing containing the protein collagen.
- ◇ **Other products:** Transcyte® is a similar product that adds human fibroblasts to the base of the Biobrane® dressing. These secrete growth factors and proteins that also help the wound to heal.



Permanent options vary as well. Often, skin grafting is combined with a previous artificial substi-

tute of the deeper skin layers. For example, an Acellular human dermal allograft (Alloderm®) can be applied below a thin autograft. This replaces part of the dermis, the lower

skin layer, and therefore reduces scarring. Another possibility is to use so called “test tube” skin, or more scientifically, a cultured epidermal autograft (CEA)¹. This involves taking a small sample of healthy skin from the patient and growing these cells into larger sheets. These can then be applied in a similar way as an autograft, though they are less stable and lack the dermis².

Prognosis

In burn patients, the prognosis depends mostly on the percentage of the body area that is affected and the patients’ age. Serious complications include infection of the wound and consequently sepsis as well as a fluid loss that is too extreme for the body to compensate³.

 ¹ American Burn Association White Paper

 ¹ American Burn Association White Paper

 ² <http://www.burn-recovery.org/skin-grafts.htm>

 ³ <http://en.wikipedia.org/wiki/Burn>

AUSTRALIAN LIFE SCIENCE

Tissue Therapies

Tissue therapies is an ASX-listed biotech company that has developed a product that may well be useful to treat burn wounds in the future: VitroGro.

It has already been shown in clinical trials that VitroGro is effective when treating chronic wounds. In a recent release of the latest developments of their clinical trials, the company stated that the size of venous ulcers decreased by 39.2% on average over the course of a 24-day treatment with VitroGro, a statistically



significant result. Even more exceptional, according to CEO Dr. Steven Mercer, when considering that “up to 50% of diabetic and venous ulcers remain unhealed after 20 weeks of expert treatment.”¹

VitroGro can be used both in research and in wound-treatment, both as a stand-alone product or in combination with dressings. It consists of a sophisticated human extracellular matrix protein that is manufactured to exacting standards, that can then be used to enhance the growth and migration of cells in

cell cultures as well as in healing wounds. Considering the risk of BSE, the cost of proteins derived from foetal bovine serum used routinely for similar purposes, have exploded in the past 8 years. VitroGro is therefore a cost-effective alternative². Only very small doses 1 or 2 times per week are needed to achieve results.

In January of this year, Tissue Therapies signed a manufacturing contract with Eurogentec SA of Belgium for the commercial-scale, Good Manufacturing Practice production of

VitroGro, which will be used in a European human trial later this year³.

According to CEO Dr. Steven Mercer, the company’s goal is to make VitroGro the default wound healing technology for acute as well as chronic wounds.⁴ As a reminder of the size of this problem: 5% of hospitalized burn victims do not survive their injuries and 50% of patients with diabetic ulcers only survive an amputation by three years.



¹ <http://biotechnologynews.net/storyview.asp?storyid=1136860§ionsource=s0&highlight=tissue>



² <http://www.tissuetherapies.com/technology/background/>



^{3,4} http://www.tissuetherapies.com/investors/100316%20TIS_Investor%20Newsletter%20March%202010_final_low%20res.pdf

AUSTRALIAN LIFE SCIENCE

Disclaimer

The information and opinions given in this report have been drawn up by Dr. Reuter Investor Relations & European-Australian IR. This report has been exclusively published for informative purposes and represents neither a request, quotation nor a recommendation for buying or selling investment instruments or for effecting other transactions. Moreover, neither this publication nor its information forms the basis for a contract or a commitment of any kind. Any investment in shares, loans and options is faced with risks.

The information and data come from sources which Dr Reuter Investor Relations & European-Australian IR considers to be reliable. However, Dr Reuter Investor Relations & European-Australian IR does not assume any responsibility for the correctness and completeness of the information and data. Neither the writer nor Dr. Reuter Investor Relations & European-Australian IR are liable for losses or damage of any kind in connection with the content of this information brochure. By accepting this document you agree to the provisions previously noted as being mandatory for the recipient. Share prices can vary and corporate value can rise/fall. Any reference to the previous trend in value is not necessarily an indicator of developments to come. Rates of exchange can adversely affect the value trend, price and earnings of any company mentioned here. Reference is also made here to possible political, economic, credit, foreign exchange and market risks. Investment in any of the companies mentioned should only be done after studying the most recent brochure and other company/market information available and /or obtaining appropriate professional advice. Corporate brochures can be obtained from the companies in question. The reader should evaluate any investment in any of the companies mentioned here in the light of their own professional advice, circumstances and investment goals. The recommendation of Dr Reuter Investor Relations & European-Australian IR - in the event of any investments - is to consult a qualified professional consultant as to the specific financial risks and the statutory, official, credit, fiscal and settlement-induced consequences. It is quite possible that the issuers of the securities mentioned here have acted at variance to the facts of the case specified herein without Dr. Reuter Investor Relations & European-Australian IR being aware of this development.

In drawing up this paper, the following conflicts of interest cannot be categorically ruled out:

1. The companies specified may be Dr. Reuter Investor Relations & European-Australian IR customers and this publication is undertaken as part of the investor relations service package.
2. This publication was presented to the companies specified before publication and may have been changed at the company's request.
3. Dr Reuter Investor Relations & European-Australian IR and/or an affiliated company or the writer may have long or short positions in the companies specified.

This paper includes the following possible conflicts of interest: 1), 2): Phylogica & Tissue Therapies are Dr. Reuter Investor Relations & European-Australian IR customers. None of the other companies mentioned here are currently customers of Dr. Reuter Investor Relations & European-Australian IR.

Some of the following detailed statements are based on translations of corporate news and company documentation. No liability is assumed for the translations. Please refer to the original English notifications and original documents.

Disclaimer United States:

1. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
2. This news release does not constitute an offer to sell or other solicitation of an offer to buy any ordinary shares within the United States. The ordinary shares have not been offered and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws. Accordingly, the ordinary shares may not be offered or sold in the United States or to U.S. Persons (as such terms are defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is granted.
3. Information and investment comments are independently and thoroughly researched and believed correct. No guaranty of absolute accuracy can be given however. Investment decisions are fully made for own risk.

AUSTRALIAN LIFE SCIENCE

DR REUTER IR & EUROPE-AUSTRALIA IR



Company

Fact Sheets



AUSTRALIAN LIFE SCIENCE

Phylogica




Chart Development Phylogica, exchange Sydney, 6 month chart

Source: Comdirect

Field of activity

Phylogica has discovered and developed a unique proprietary class of targeted peptide therapeutics (Phylomer® peptides). These peptides exhibit competitive therapeutic, manufacturing, and commercial advantages over other more traditional targeted biologics such as proteins, monoclonal antibodies and most current therapeutic peptides. The hit to target ratios from Phylomer® libraries are high and the proportion of hits which are functional, is also very high.

Download Company Presentation



www.dr-reuter.eu/images/download/phylogica.pdf

Ratios

Symbol:	PYC
Homepage:	www.phylogica.com
Market capitalisation (23 June)	18,86 mio. AUD
52W High	0,14
52W Low	0,046
Price % Chg 4-Wk/52Wk:	0/+66,67%
Government grant income 08/09:	1,273,780 AUD
Commercial income 08/09:	1,162 AUD
Loss before income tax 08/09:	4,490,920 AUD

Source: comdirect, Phylogica Annual Report 2009

Company Highlights

- ◇ Unique drug discovery resource for pharmaceutical industry
- ◇ Technology is fully validated, scalable and optimized for commercialization
- ◇ Broad patent protection for entire class of drugs
- ◇ Initiated commercialization phase, several late-stage deal negotiations
- ◇ Strategy for near-term cash-sustainability, driven by fee-for-service drug discovery
- ◇ Objective to secure an increasing share of down-stream value through co-development

Source: Phylogica

Latest News

- ◇ **19 May 2010: Rodman and Renshaw Global Healthcare Conference Presentation**



<http://www.asx.com.au/asxpdf/20100519/pdf/31qdt6fx77vdc8.pdf>

- ◇ **18 May 2010: Frankfurt Stock Exchange Listing**



<http://www.asx.com.au/asxpdf/20100518/pdf/31qd5zmrktyw48.pdf>

- ◇ **30 April 2010: Appendix 4C - quarterly**



<http://www.asx.com.au/asxpdf/20100430/pdf/31q2ngwzlv0f2.pdf>

AUSTRALIAN LIFE SCIENCE

Starpharma




Chart development Starpharma, exchange Sydney, 6 month chart

Source: Comdirect

Ratios

Symbol:	SPL
Website	www.starpharma.com
Market capitalisation (23 June):	A\$127,76 Mio.
52W High	A\$ 0,75
52W Low	A\$ 0,31
Revenues 08 / 09:	A\$ 9,81 Mio.
EBITDA 08 / 09:	A\$ (- 2,30) Mio.
EBIT 08 / 09:	A\$ (-4,13) Mio.

Source: Reuters Knowledge, Starpharma


Field of activity & Pipeline

Starpharma is a world leader in the development of nanotechnology-based pharmaceuticals and, through its US-based subsidiary Dendritic Nanotechnologies (DNT), a range of life-science and industrial uses.

Intellectual Property

Starpharma holds a central position in the dendrimer IP landscape with a wide portfolio of patents and patent applications covering both the composition and application of dendrimers in pharmaceutical and life-science fields.

Pharmaceutical and Life Sciences Product Pipeline




*Condom coating has the potential for an accelerated development program

AUSTRALIAN LIFE SCIENCE

DR REUTER IR & EUROPE-AUSTRALIA IR

Tissue Therapies



Tissue Therapies, exchange Sydney, 6 month chart

Source: Comdirect

Field of activity

Tissue Therapies Ltd provides wound healing, tissue repair and cell culture technology through a novel growth factor platform technology VitroGro®. VitroGro® is an animal product free, multimeric delivery system for growth factors, enhancing cell replication, protein synthesis and migration.

Download Documents



Annual Report

www.asx.com.au/asxpdf/20091008/pdf/3116grtc9kbrz0.pdf



Company Presentation

www.dr-reuter.eu/images/download/tmay10.pdf

Wound Healing



Tissue Therapies: Wound Healing (especially Venous Ulcers & Diabetic Ulcers)

Ratios

Symbol:	TIS
Website	www.tissuetherapies.com
Market capitalisation (23June):	A\$27,64 Mio.
Price % Chg 4-Wk/52Wk:	14,29%/ 17,65%
Revenues 08 / 09:	A\$ 0.28 Mio.
Loss before income tax benefit	A\$ (- 4.7) Mio.

Source: Annual Report Tissue Therapies, Comdirect

Latest News

Click on the link under the header to download the release

17 June 2010: More Exceptional Results for VitroGro

<http://asx.com.au/asxpdf/20100617/pdf/31qw26x3mx8fwv.pdf>

16 April 2010: Appendix 4C - quarterly

www.asx.com.au/asxpdf/20100416/pdf/31pt757j5vhf7k.pdf

15 March 2010: Investor Update March 2010

www.asx.com.au/asxpdf/20100315/pdf/31p8ddh3tb97tv.pdf

09 March 2010: Executive Remuneration Strategy

www.asx.com.au/asxpdf/20100309/pdf/31p4rcky9bx858.pdf

AUSTRALIAN LIFE SCIENCE

Australian Life Science Company name	Market Cap in Mio. A\$	Description	Sector
1300 SMILES LTD	ONT	55 Provision of dental surgeries and practice management to self-employed dentists.	H.C. & S
ACRUX LTD	ACR	390 A development fund that invests in pharmaceutical businesses developing new products involving the delivery of pharmaceuticals via the skin	P., B. & LS
ACTINOGEN LTD	ACW	2 Commercialisation of bioactive compounds	P., B. & LS
ACUVAX (former Avantogen)	ACU	12 Cancer drug development.	P., B. & LS
ADVANCED SUR. DESIGN & MANUF.	AMT	20 Developer and manufacturer of prosthetic implants and medical devices.	H.C. & S
AEVUM LTD	AVE	177 Owns and operates twenty one senior living communities in Sydney, mid-North Coast, Southern Highlands of NSW, and Western Australia.	H.C. & S
AGENIX LTD	AGX	Research, development, manufacture and sale of pharmaceuticals; biotechnology development and manufacture and sale of biochemicals.	P., B. & LS
ALCHEMIA LTD	ACL	126 The development of carbohydrate-based molecules for therapeutic applications	P., B. & LS
ANALYTICA LTD	ALT	26 Analytica Limited is a medical technology company. Existing operations include Retractable Technologies and Diagnostic Trading.	H.C. & S
ANSELL LTD	ANN	1423 Development, manufacturing and sourcing, distribution and sale of gloves and protective products.	H.C. & S
ANTEO DIAGNOSTICS	ADO	3 Developing and commercialising medical products.	P., B. & LS
ANTISENSE THERAPEUTICS LTD	ANP	34 The development of novel antisense pharmaceuticals for commercially important human conditions.	P., B. & LS
AQUACAROTENE LTD	AQL	3 The growth, harvesting, refinement, promotion and sale of Natural betaCarotene.	H.C. & S
ASCENT PHARMAHEALTH LTD	APH	49 Marketing and distribution of pharmaceuticals	P., B. & LS

You may download the whole list under:

 www.dr-reuter.eu/images/download/austbiocompanies.pdf



AUSTRALIAN LIFE SCIENCE



Fairs

&

Congresses




DR REUTER IR & EUROPE-AUSTRALIA IR

AUSTRALIAN LIFE SCIENCE

2nd WIN Symposium– Worldwide Innovative Networking in Personalized Cancer medicine

06-08 July 2010, Paris, France

This event, entitled Worldwide Innovative Networking in Personalized Cancer Medicine 2010 (WIN 2010), will present breakthrough scientific technologies and achievements in personalized cancer medicine, with a special focus on individualized treatment and early diagnosis of cancer. The symposium will offer an interactive forum to discuss new approaches, tools and challenges in cancer medicine.



QUICK FACTS

WHEN?
06-08 July 2010

WHERE?
Paris, France

MORE INFORMATION
<http://www.mfcongres.com/>

CONTACT
+33-1-40071121
info@mfcongres.com

3rd International Congress on Stem Cells and Tissue Formation 2010

10-13 July, Dresden, Germany

The congress will focus on stem cells, and the formation of tissues of multiple organs, such as the CNS, pancreas, skin, heart, and the hematopoietic system.



QUICK FACTS

WHEN?
10-13 July

WHERE?
Dresden, Germany

MORE INFORMATION
www.stemcellcongress-dresden.org

CONTACT
a.enke@interplan.de

AUSTRALIAN LIFE SCIENCE

REMEDIIS 2010

15-18 July 2010, Iasi, Romania

International conference concerning regenerative medicine. Main topics: Neuroregeneration; Musculoskeletal regeneration; Cardiac muscle regeneration; Cord blood stem cells and their potential in regenerative Medicine, Airway and lung regeneration; Biomaterials as scaffolds in regenerative medicine; From bench to bedside – a biotech company position.



QUICK FACTS

WHEN?
15-18 July 2010

WHERE?
Iasi, Romania


MORE INFORMATION
www.remedis.info

CONTACT
luminita.simion@remedis.info

WorldPharma2010

17-23 July 2010, Copenhagen, Denmark

16th World Congress of Basic and Clinical Pharmacology organised by the Danish Pharmacology Society.



QUICK FACTS

WHEN?
17-23 July 2010

WHERE?
Copenhagen, Denmark

MORE INFORMATION
www.worldpharma2010.org

CONTACT
WorldPharma2010@ics.dk

AUSTRALIAN LIFE SCIENCE

Creating Value from Biobanking

21-22 July 2010, Frankfurt a.M., Germany

With biobanking experts and scientific leaders (and end-users) discussing the critical challenges and opportunities for successful biosample management in human disease research. Workshops 20 & 23 July.



QUICK FACTS

WHEN?
21-22 July 2010

WHERE?
Frankfurt a.M., Germany

MORE INFORMATION
www.biorbis.com

CONTACT
Phone: +44-203-141-8700
info@hansonwade.com

NanoBio 2010

24-27 August 2010, Zurich, Switzerland

This meeting gathers the leaders of this progressive field from all over the world helping scientists to get an update on the most recent achievements in the different topics of nanobiotechnology, to discuss, to network, to exchange stimulating new ideas, and to take responsibility in forming public opinion about nanobiotechnology.



QUICK FACTS

WHEN?
24-27 August 2010

WHERE?
Zurich, Switzerland

MORE INFORMATION
<http://www.nanobio.ethz.ch/>

CONTACT
+41-44-632-45 85
nanobio@ethz.ch

AUSTRALIAN LIFE SCIENCE

5th International Congress on Biocatalysis

29 Aug.– 02 Sept. 2010, Hamburg, Germany

Since 2002 we have been organizing the biocat conference series, which focuses on the rapidly evolving fields of biocatalysis and industrial biotechnology. The successful concept of biocat is due to an interdisciplinary approach integrating the know-how of well acknowledged biologists, biochemists, chemists and engineers from academia and industry. They will discuss chances for new products and environment-friendly processes.



QUICK FACTS

WHEN?

29 August– 02 September

WHERE?

Hamburg, Germany

MORE INFORMATION

www.biocat2010.de

CONTACT

+49-40-76629-6551

loebkensy@tutech.de

EMBO Meeting 2010

04-07 September 2010, Barcelona, Spain

Fast-paced conceptual and technological advances are profoundly changing the landscape of molecular biology research in terms of the depth and nature of biological insights gained. We are particularly excited to organize and present the programme for The EMBO Meeting 2010 to highlight the dynamism of the field and feature many leading researchers as speakers. The EMBO Meeting 2010 promises a vibrant platform for scientific exchange between leading researchers and young molecular biologists just starting out on their rese-



QUICK FACTS

WHEN?

04-07 September 2010

WHERE?

Barcelona, Spain

MORE INFORMATION


www.the-embo-meeting.org

CONTACT

+49-6221-8891-106

AUSTRALIAN LIFE SCIENCE

DR REUTER IR & EUROPE-AUSTRALIA IR



Dr Reuter Investor Relations

Specialist in investor relations work on the European capital markets

Dr. Eva Reuter
 Mobile: +49-177-6058804
 e.reuter@dr-reuter.eu
 www.dr-reuter.eu

Office UK:
 London,
 United Kingdom
 Office +44 (0) 20 7193
 6458

Office Germany:
 Annette-Allee 6
 48149 Munster
 Germany
 Office +49 (0)251 71 32 862



Europe-Australia Investor Relations

Trevor Baldock
 Managing Partner
 Mobile: +33 6 08 787 104
 tbaldock@dr-reuter.eu
 www.dr-reuter.eu

Office France
 Galaxy 222
 6 bis Rue de la Paroisse
 78000 Versailles, France

